105 related articles for article (PubMed ID: 14726696)
1. An Arf(GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo.
Sherr CJ
Cell Cycle; 2004 Mar; 3(3):239-40. PubMed ID: 14726696
[TBL] [Abstract][Full Text] [Related]
2. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo.
Zindy F; Williams RT; Baudino TA; Rehg JE; Skapek SX; Cleveland JL; Roussel MF; Sherr CJ
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15930-5. PubMed ID: 14665695
[TBL] [Abstract][Full Text] [Related]
3. Certainly no ARFterthought: oncogenic cooperation in ARF induction a key step in tumor suppression.
Haupt Y
Cell Cycle; 2003; 2(2):113-5. PubMed ID: 12695659
[No Abstract] [Full Text] [Related]
4. The Arf tumor suppressor regulates platelet-derived growth factor receptor beta signaling: a new view through the eyes of Arf(-/-) mice.
Thornton JD; Silva RL; Martin AC; Skapek SX
Cell Cycle; 2005 Oct; 4(10):1316-9. PubMed ID: 16205116
[TBL] [Abstract][Full Text] [Related]
5. Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye.
Silva RL; Thornton JD; Martin AC; Rehg JE; Bertwistle D; Zindy F; Skapek SX
EMBO J; 2005 Aug; 24(15):2803-14. PubMed ID: 16037818
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.
Bertwistle D; Sherr CJ
Blood; 2007 Jan; 109(2):792-4. PubMed ID: 16968893
[TBL] [Abstract][Full Text] [Related]
7. N-terminal polyubiquitination and degradation of the Arf tumor suppressor.
Kuo ML; den Besten W; Bertwistle D; Roussel MF; Sherr CJ
Genes Dev; 2004 Aug; 18(15):1862-74. PubMed ID: 15289458
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene.
Martin AC; Thornton JD; Liu J; Wang X; Zuo J; Jablonski MM; Chaum E; Zindy F; Skapek SX
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3387-96. PubMed ID: 15452040
[TBL] [Abstract][Full Text] [Related]
9. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development.
McKeller RN; Fowler JL; Cunningham JJ; Warner N; Smeyne RJ; Zindy F; Skapek SX
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3848-53. PubMed ID: 11891301
[TBL] [Abstract][Full Text] [Related]
10. AP-1 dimers regulate transcription of the p14/p19ARF tumor suppressor gene.
Ameyar-Zazoua M; Wisniewska MB; Bakiri L; Wagner EF; Yaniv M; Weitzman JB
Oncogene; 2005 Mar; 24(14):2298-306. PubMed ID: 15688012
[TBL] [Abstract][Full Text] [Related]
11. Role of INK4a/Arf locus-encoded senescent checkpoints activated in normal and psoriatic keratinocytes.
Chaturvedi V; Cesnjaj M; Bacon P; Panella J; Choubey D; Diaz MO; Nickoloff BJ
Am J Pathol; 2003 Jan; 162(1):161-70. PubMed ID: 12507899
[TBL] [Abstract][Full Text] [Related]
12. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
13. A new mechanism of inactivation of the INK4/ARF locus.
Gonzalez S; Serrano M
Cell Cycle; 2006 Jul; 5(13):1382-4. PubMed ID: 16855387
[TBL] [Abstract][Full Text] [Related]
14. The inv(16) cooperates with ARF haploinsufficiency to induce acute myeloid leukemia.
Moreno-Miralles I; Pan L; Keates-Baleeiro J; Durst-Goodwin K; Yang C; Kim HG; Thompson MA; Klug CA; Cleveland JL; Hiebert SW
J Biol Chem; 2005 Dec; 280(48):40097-103. PubMed ID: 16199529
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel ARF binding proteins by two-hybrid screening.
Tompkins V; Hagen J; Zediak VP; Quelle DE
Cell Cycle; 2006 Mar; 5(6):641-6. PubMed ID: 16582619
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus.
Gonzalez S; Klatt P; Delgado S; Conde E; Lopez-Rios F; Sanchez-Cespedes M; Mendez J; Antequera F; Serrano M
Nature; 2006 Mar; 440(7084):702-6. PubMed ID: 16572177
[TBL] [Abstract][Full Text] [Related]
17. p53-Dependent and -independent functions of the Arf tumor suppressor.
Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitination of, and sumoylation by, the Arf tumor suppressor.
den Besten W; Kuo ML; Tago K; Williams RT; Sherr CJ
Isr Med Assoc J; 2006 Apr; 8(4):249-51. PubMed ID: 16671360
[TBL] [Abstract][Full Text] [Related]
19. The ARF tumor suppressor: keeping Myc on a leash.
Gregory MA; Qi Y; Hann SR
Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
[TBL] [Abstract][Full Text] [Related]
20. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
Russell JL; Weaks RL; Berton TR; Johnson DG
Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
